Apollomics Inc. (APLMW) — 6-K Filings

6-K Filings (27)

• Apollomics Inc. Files 6-K with Mid-Year Financials — Dec 22, 2025 Risk: medium
  Apollomics Inc. filed a 6-K report on December 22, 2025, detailing financial information for the period ending June 30, 2025. The filing includes information on
• 6-K Filing — Dec 12, 2025
• 6-K Filing — Nov 19, 2025
• 6-K Filing — Nov 18, 2025
• Apollomics: LaunXP Payment Still Pending — Oct 21, 2025 Risk: medium
  Apollomics Inc. filed a 6-K on October 21, 2025, providing an update on its agreement with LaunXP International Co., Ltd. The filing states that LaunXP has not
• Apollomics Inc. Changes Auditors — Oct 16, 2025 Risk: medium
  On October 13, 2025, Apollomics Inc. dismissed Grant Thornton LLP as its independent registered public accounting firm. The company's Audit Committee subsequent
• Apollomics Inc. Updates Operations, Focuses on Oncology Pipeline — Oct 14, 2025 Risk: low
  Apollomics Inc. provided an operational continuity update on October 14, 2025. The clinical-stage biotechnology company is focused on advancing innovative oncol
• Apollomics Faces Nasdaq Delisting — Sep 25, 2025 Risk: high
  Apollomics Inc. received a delisting notice from Nasdaq on September 22, 2025, stating that its securities will be delisted unless the company requests an appea
• Apollomics Appoints Two New Directors to Board — Sep 5, 2025 Risk: low
  Apollomics Inc. announced on September 4, 2025, the appointment of Yi-An Chu and Chen-Huan Jan as directors to its Board. This expands the Board to seven member
• Apollomics Closes Private Placement — Sep 3, 2025 Risk: medium
  On September 2, 2025, Apollomics Inc. entered into PIPE Subscription Agreements with certain accredited investors. The private placement, known as the PIPE, clo
• Apollomics Terminates US Staff, Halts SPARTA Trial — Aug 28, 2025 Risk: high
  On August 28, 2025, Apollomics Inc. announced the termination of all U.S. employees, including CEO Dr. Guo-Liang Yu and CFO Dr. Matthew Plunkett, effective Augu
• Apollomics Licenses Vebreltinib Rights in Asia — Jul 25, 2025 Risk: medium
  On March 31, 2025, Apollomics Inc. announced an agreement for the development and commercialization of its proprietary c-Met inhibitor, vebreltinib, in Asia (ex
• Apollomics inks Asia deal for NSCLC drug vebreltinib — Mar 31, 2025 Risk: medium
  On March 31, 2025, Apollomics Inc. announced a new agreement for the development and commercialization of its proprietary c-Met inhibitor, vebreltinib, in combi
• Apollomics Inc. Reports Phase 3 Trial Results for Uproleselan — Dec 20, 2024 Risk: medium
  On December 20, 2024, Apollomics Inc. announced the results of its Phase 3 bridging trial for uproleselan in China. The company issued a press release detailing
• Apollomics Regains Nasdaq Bid Price Compliance — Dec 10, 2024 Risk: low
  On December 10, 2024, Apollomics Inc. announced it has received a notice from Nasdaq confirming it has regained compliance with the minimum closing bid price re
• Apollomics Holds Shareholder Meeting — Nov 14, 2024 Risk: low
  Apollomics Inc. held its Extraordinary General Meeting of Shareholders on November 14, 2024. Shareholders representing 40,155,852 shares, out of 110,266,527 out
• Apollomics Inc. Files 6-K for Shareholder Meeting — Nov 1, 2024 Risk: low
  Apollomics Inc. is furnishing a report on Form 6-K for November 2024. This filing includes the notice and proxy statement for an Extraordinary General Meeting o
• Apollomics Inc. Files 6-K for Q2 2024 — Aug 14, 2024 Risk: low
  Apollomics Inc. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data and details related to share classes and warrants, su
• Apollomics Announces Executive Departures — Aug 1, 2024 Risk: medium
  On August 1, 2024, Apollomics Inc. announced the departure of Sanjeev Redkar, Ph.D., co-founder and President, and Peony Yu, M.D., Chief Medical Officer. These
• Apollomics Gets 180-Day Nasdaq Bid Price Extension — Jul 16, 2024 Risk: medium
  Apollomics Inc. received a notice from Nasdaq on July 16, 2024, indicating it has not yet regained compliance with the minimum bid price requirement. However, t
• Apollomics Inc. Updates Strategy and Leadership — Jul 3, 2024 Risk: medium
  On July 3, 2024, Apollomics Inc. announced an updated strategic focus and changes to its leadership team via a press release. The company is furnishing this pre
• Apollomics Inc. Launches "At the Market" Sales Program — May 24, 2024 Risk: medium
  On May 24, 2024, Apollomics Inc. entered into a Sales Agreement with Cantor Fitzgerald & Co. as sales agent to establish an "At the Market" sales program. This
• Apollomics Inc. Enters Private Placement Agreements — May 8, 2024 Risk: medium
  On May 6, 2024, Apollomics Inc. entered into PIPE Subscription Agreements with certain accredited investors for a private placement. The closing of this private
• Apollomics Inc. Updates Investor Presentation — Apr 25, 2024 Risk: low
  On April 25, 2024, Apollomics Inc. posted updated presentation materials on its investor relations website. These materials are available for review by investor
• Apollomics Appoints New CFO, Matthew Plunkett — Mar 4, 2024 Risk: low
  Apollomics Inc. announced on March 4, 2024, the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer (CFO), effective immediately. Dr. Plu
• APLM Gets Nasdaq Delisting Warning for Sub-$1.00 Bid Price — Jan 19, 2024
  Apollomics Inc. (APLM) received a notice from Nasdaq on January 16, 2024, indicating non-compliance with the minimum $1.00 bid price requirement. The company no
• Apollomics Posts New Investor Presentation Materials Online — Jan 8, 2024
  On January 8, 2024, Apollomics Inc. filed a 6-K to announce they posted new investor presentation materials on their website. This filing itself doesn't contain

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX